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Conclusions  
 
 
 
Introduction 
 
Methods 
Results 
Various cardiac abnormalities, including dysrhythmias, 
left ventricular (LV) dysfunction, and myocardial injury, 
are commonly seen after subarachnoid hemorrhage 
(SAH). In patients taking a beta-blocker (BB) chronically, 
the medication is generally discontinued after 
hospitalization due to the concern of compromising 
cerebral perfusion. We hypothesized that sudden BB 
discontinuation might inadvertently lead to an increased 
incidence of composite cardiac abnormalities and higher 
in-hospital mortality in patients presenting with non-
traumatic SAH.  
 
This is a single-center retrospective study of patients 
presenting to Thomas Jefferson University Hospital 
and Jefferson Hospital for Neuroscience with ruptured 
aneurysmal SAH between January 2009 and 
December 2010. Those with and without preadmission 
BB use were compared with respect to the composite 
cardiac abnormalities (troponin elevation and/or LV 
dysfunction) and in-hospital mortality. Troponin 
elevation and LV dysfunction were defined as troponin 
I ≥ 0.05 mcg/L, and LV ejection fraction ≤ 0.4, 
respectively. Variables with p<0.10 in a univariate 
analysis were included in a multivariable logistic 
regression model to determine the effect of BB 
discontinuation on the clinical outcomes.  
 
1. Preadmission BB use and its discontinuation was not 
associated with the composite cardiac abnormalities 
or in-hospital mortality.  
2. Sudden BB discontinuation after SAH does not 
appear to be associated with adverse cardiovascular 
outcomes.  
3. Elevated troponin was independently associated with 
increased in-hospital mortality.  
Of 414 patients presenting with aneurysmal SAH, 55 
(13%) patients were chronic BB users.  In 273 patients 
with both troponin and echo results, the composite 
cardiac abnormalities occurred in 145 patients (53%). 
Preadmission BB use was not associated with the 
composite cardiac abnormalities in the multivariable 
analysis (p=0.51). (Table 1) Fifty-two out of 273 (19%) 
patients died during the index hospitalization.  Troponin 
elevation, but neither LV dysfunction nor outpatient BB 
use, was independently associated with increased in-
hospital mortality (p=0.01). (Table 2) 
Results 
  OR for composite 
cardiac outcome 
95%  CI p-value* 
Hunt-Hess  
1-3 vs 4,5 
3.9 (2.2- 6.7) <0.001 
Hypertension 1.7 (0.97-2.9) 0.07 
Outpatient BB 
use 
1.3 (0.6-2.8) 0.51 
  OR for in-hospital 
mortality 
95%  CI p-value* 
Hunt-Hess  
1-3 vs 4,5 
15.2 (6.2-37.4) <0.001 
Coronary artery 
disease 
3.9 (1.2-13.3) 0.03 
Outpatient BB 
use 
1.4 (0.5-4.1) 0.56 
Abnormal 
Troponin 
3.3 (1.3-8.5) 0.01 
Abnormal LV 
function 
2.1 (0.9-5.2) 0.1 
Table 1. A multivariable analysis for the composite cardiac abnormalities. 
A p value < 0.05 is statistically significant.  OR=odds ratio, CI=confidence 
interval.  
Table 2. A multivariable analysis for in-hospital mortality. A p value < 0.05 
is statistically significant.    
Patients with non-
traumatic SAH 
(N=414) 
Composite 
Cardiovascular 
Abnormalities  
In-hospital Mortality  
Troponin elevation 
and/or LV 
dysfunction 
(N=24, 63%) 
Troponin elevation 
and/or LV 
dysfunction 
(N=121, 52%) 
Death 
(N=10, 26%)   
Death 
(N=42, 18%)   
Both troponin 
and echo 
results available  
(N=273) 
Chronic BB use 
N=38 
No BB use 
N=235 
Study overview 
